Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family

Breast Cancer Research and Treatment

Volumn 58, Issue 1, 1999, Pages 41-56

  Larsen, Søren S ^a,b   Egeblad, Mikala ^b   Jäättelä, Marja ^b   Lykkesfeldt, Anne E ^a  

^a Department of Tumor Endocrinology ^*  (Denmark)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

Antiestrogens; EGFR; HER 2 neu; Heregulinl 1; MCF 7; Resistance

Indexed keywords

ANTIESTROGEN; CELL RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; NEU DIFFERENTIATION FACTOR; TAMOXIFEN; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG RESISTANCE; EXPRESSION VECTOR; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

BLOTTING, NORTHERN; BLOTTING, WESTERN; BREAST NEOPLASMS; DNA PRIMERS; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; POLYUNSATURATED ALKAMIDES; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0033429237     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006232830161     Document Type: Article

References (66)

1. 1. Rajkumar T, Gullick WJ: The type I growth factor receptors in human breast cancer. Breast Cancer Res Treat 29: 3-9, 1994
2. 2. Carpenter G, Cohen S: Epidermal growth factor. Annu Rev Biochem 48: 1979
3. 3. Coussens L, Yang FT, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, Levinson A, Ullrich A: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132-1139, 1985
4. 4. King CR, Kraus MH, Aaronson SA: Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229: 974-976, 1985
5. 5. Plowman GD, Culouscou JM, Whitney GS, Green JM, Carlton GW, Foy L, neubauer MG, Shoyab, M: Ligand-specific activation of HER4/pl80erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 90: 1746-1750, 1993
6. 6. Kraus MH, Fedi P, Starks V, Muraro R, Aaronson SA: Demonstration of liganddependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells. Proc Natl Acad Sci USA 90: 2900-2904, 1993
7. 7. Carraway KL, Cantley LC: A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 78: 5-8, 1994
8. 8. Sainsbury JR, Farndon JR, Sherbet GV, Harris AL: Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet i: 364-366, 1985
9. 9. Davidson NE, Gelmann EP, Lippman ME, Dickson RB: Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol.Endocrinol 1: 216-223, 1987
10. 10. Klijn JG, Look MP, Portengen H, Alexieva FJ, van PW, Foekens JA: The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study. Breast Cancer Res Treat 29: 73-83, 1994
11. 11. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL: Epidermalgrowth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet i: 1398-1402, 1987
12. 12. Harris AL, Nicholson S, Sainsbury JR, Farndon J, Wright C: Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. J Steroid Biochem 34: 123-131, 1989
13. 13. Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, Robertson JF, Ellis IO, Blamey RW: Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat 29: 117-125, 1994
14. 14. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER2/ncu oncogene. Science 235: 177-182, 1987
15. 15. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244: 707-712, 1989
16. 16. Wright C, Nicholson S, Angus B, Sainsbury JR, Farndon J, Cairns J, Harris AL, Horne CM: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65: 118-121, 1992
17. 17. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Ryden S, Sigurdsson H: ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 81: 137-144, 1994
18. 18. Revillion F, Bonneterre J, Peyrat JP: ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34: 791-808, 1998
19. 19. Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA: Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA 86: 9193-9197, 1989
20. 20. Lemoine NR, Barnes DM, Hollywood DP, Hughes CM, Smith P, Dublin E, Prigent SA, Gullick WJ, Hurst HC: Expression of the ERBB3 gene product in breast cancer. Br J Cancer 66: 1116-1121, 1992
21. 21. Travis A, Pinder SE, Robertson JF, Bell JA, Wencyk P, Gullick WJ, Nicholson RI, Poller DN, Blamey RW, Elston CW, Ellis IO: C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer 74: 229-233, 1996
22. 22. Vogt U, Bielawski K, Schlotter, CM, Bosse U, Falkiewicz, B, Podhajska AJ: Amplification of erbB-4 oncogene occurs less frequently than that of erbB-2 in primary human breast cancer. Gene 233: 375-380, 1998
23. 23. Lykkesfeldt AE, Sørensen EK: Effect of estrogen and anti-estrogens on cell proliferation and synthesis of secreted proteins in the human breast cancer cell line MCF-7 and a tamoxifen resistant variant subline, AL-1. Acta Oncol 31: 131-138, 1992
24. R-1. Cancer Res 54: 1587-1595, 1994
25. 25. Lykkesfeldt AE, Larsen SS, Briand P: Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. Int J Cancer 61: 529-534, 1995
26. 26. Larsen SS, Madsen MW, Jensen BL, Lykkesfeldt AE: Resistance of human breast-cancer cells to the pure steroidal anti-estrogen ICI 182,780 is not associated with a general loss of estrogen-receptor expression or lack of estrogen responsiveness. Int J Cancer 72: 1129-1136, 1997
27. 27. Madsen MW, Reiter BE, Larsen SS, Briand P, Lykkesfeldt AE: Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells. Cancer Res 57: 585-589, 1997
28. 28. Osborne CK, Fuqua SA: Mechanisms of tamoxifen resistance. Breast Cancer Res Treat 32: 49-55, 1994
29. 29. Lykkesfeldt AE: Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer. Acta Oncol 35 (Suppl 5) 1996
30. 30. Katzenellenbogen BS, Montano MM, Ekena K, Herman ME, Melnerney EM: William L. McGuire Memorial Lecture. Anti-estrogens: mechanisms of action and resistance in breast cancer. Breast Cancer Res Treat 44: 23-38, 1997
31. 31. Johnston SR: Acquired tamoxifen resistance in human breast cancer-potential mechanisms and clinical implications. Anti-cancer Drugs 8: 911-930, 1997
32. 32. Miller DL, El-Ashry D, Cheville AL, Liu Y, McLeskey SW, Kern FG: Emergence of MCF-7 cells overexpressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: evidence for a role of EGFR in breast cancer growth and progression. Cell Growth Differ 5: 1263-1274, 1994
33. 33. Van Agthoven TT, van Agthoven TL, Portengen H, Foekens JA, Dorssers, LC: Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. Cancer Res 52: 5082-5088, 1992
34. 34. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK: Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24: 85-95, 1992
35. 35. Lupu R, Cardillo M, Cho C, Harris L, Hijazi M, Perez C, Rosenberg K, Yang D, Tang C: The significance of heregulin in breast cancer tumor progression and drug resistance. Breast Cancer ResTreat 38: 57-66, 1996
36. 36. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10: 2435-2446, 1995
37. 37. Briand P, Lykkesfeldt AE: Effect of estrogen and antiestrogen on the human breast cancer cell line MCF-7 adapted to growth at low serum concentration. Cancer Res 44: 1114-1119, 1984
38. 38. Egeblad M, Jäättelä M: Overexpression of ErbB receptor tyrosine kinases does not protect against TNF-induced apoptosis or starvation in MCF-7 breast carcinoma cells (submitted).
39. 39. Madsen MW, Lykkesfeldt AE, Laursen I, Nielsen KV, Briand P: Altered gene expression of c-myc, epidermal growth factor receptor, transforming growth factor-alpha, and c-erb-B2 in an immortalized human breast epithelial cell line, HMT-3522, is associated with decreased growth factor requirements. Cancer Res 52: 1210-1217, 1992
40. 40. Krainer AR, Maniatis T, Ruskin B, Green MR: Normal and mutant human betaglobin pre-mRNAs are faithfully and efficiently spliced in vitro. Cell 36: 993-1005, 1984
41. 41. Laborda J: 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. Nucleic Acids Res 19: 3998-3998, 1991
42. 42. Kraus MH, Popescu NC, Amsbaugh SC, King CR: Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 6: 605-610, 1987
43. 43. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WT, Rowland AM, Kotts C, Carver ME, Shepard HM: Humanization of an anti-p185(HER2) antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285-4289, 1992
44. 44. Kumar R, Shepard HM, Mendelsohn J: Regulation of phosphorylation of the cerbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells. Mol Cell Biol 11: 979-986, 1991
45. 45. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard HM: Differential responses of human tumor cell lines to anti-p185(HER2) monoclonal antibodies. Cancer Immunol. Immunother 37: 255-263, 1993
46. 46. Di Fiore PP, Segatto O, Taylor WG, Aaronson SA, Pierce JH: EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling. Science 248: 79-83, 1990
47. 47. Tang CK, Perez C, Grunt T, Waibel C, Cho C, Lupu R: Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells. Cancer Res 56: 3350-3358, 1996
48. 48. Freiss G, Prebois C, Vignon F: William L. McGuire Memorial Symposium. Control of breast cancer cell growth by steroids and growth factors: interactions and mechanisms. Breast Cancer Res Treat 27: 57-68, 1993
49. 49. Sainsbury JR, Farndon JR, Harris AL, Sherbet GV: Epidermal growth factor receptors on human breast cancers. Br J Surg 72: 186-188, 1985
50. 50. Davidson NE, Gelmann EP, Lippman ME, Dickson RB: Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol 1: 216-223, 1987
51. 51. Harris AL, Nicholson S, Sainsbury JR, Farndon J, Wright C: Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. J Steroid Biochcm 34: 123-131, 1989
52. 52. Nicholson S, Sainsbury JR, Halcrow P, Chambers P, Farndon JR, Harris AL: Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet i: 182-185, 1989
53. 53. Archer SG, Eliopoulos A, Spandidos D, Barnes D, Ellis IO, Blamey RW, Nicholson RI, Robertson JF: Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 72: 1259-1266, 1995
54. 54. Elledge RM, Green S, Ciocca D, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, O'Sullivan J, Martino S, Osborne CK: HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 4: 7-12, 1998
55. 55. Berthois Y, Dong XF, Martin PM: Regulation of epidermal growth factor-receptor by estrogen and antiestrogen in the human breast cancer cell line MCF-7. Biochem Biophys Res Commun 159: 126-131, 1989
56. 56. Yarden RI, Lauber AH, El AD, Chrysogelos SA: Bimodal regulation of epidermal growth factor receptor by estrogen in breast cancer cells. Endocrinology 137: 2739-2747, 1996
57. 57. Sepp LL, Eberhard I, Ma Z, Cho C, Serve H, Liu F, Rosen N, Lupu R: Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells. Oncogene 12: 1679-1687, 1996
58. 58. Holmes WE, Sliwkowski MX, Akita RW, Henzel WJ, Lee J, Park JW, Yansura D, Abadi N, Raab H, Lewis GD, Shepard HM, Kuang WL, Wood WI, Goeddel DV, Vandlen RL: Identification of heregulin, a specific activator of p185erbB2. Science 256: 1205-1210, 1992
59. 59. Newby JC, Johnston SR, Smith IF, Dowsett M: Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 3: 1643-1651, 1997
60. 60. Russell KS, Hung MC: Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor. Cancer Res 52: 6624-6629, 1992
61. 61. Read LD, Keith D, Slamon DJ, Katzenellenbogen BS: Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 50: 3947-3951, 1990
62. 62. Antoniotti S, Maggiora P, Dati C, DeBortoli M: Tamoxifen up-regulates c-erbB2 expression in oestrogen-responsive breast cancer cells in vitro. Eur J Cancer 28: 318-321, 1992
63. 63. Dati C, Antoniotti S, Taverna D, Perroteau I, DeBortoli M: Inhibition of c-erbB 2 oncogene expression by estrogens in human breast cancer cells. Oncogene 5: 1001-1006, 1990
64. 64. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J: Recombinant humanized anti-HER2 antibody (Herceptin(TM)) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58: 2825-2831, 1998
65. 65. Witters LM, Kumar R, Chinchilli VM, Lipton A: Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Res Treat 42: 1-5, 1997
66. 66. Liu Y, El-Ashry D, Chen D, Ding IY, Kern FG: MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifensensitivity in vivo. Breast Cancer Res Treat 34: 97-117, 1995